AstraZeneca pharma India Limited has secured a significant regulatory milestone with the Central Drugs Standard Control Organisation (CDSCO) granting permission for an expanded indication of its cancer treatment drug. The approval, received on April 9, marks an important development in the company's oncology portfolio in India.

Regulatory Approval Details

The CDSCO, under the Directorate General of Health Services, Government of India, has granted permission to AstraZeneca Pharma India Limited to import for sale and distribution of Acalabrutinib tablets 100 mg. The drug, marketed under the brand name Calquence®, has received approval for an additional therapeutic indication beyond its existing uses.

Expanded Treatment Indication

The newly approved indication allows Acalabrutinib tablets 100 mg to be used in combination therapy for treating patients with previously untreated chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). The combination therapy involves Acalabrutinib with venetoclax, with or without obinutuzumab, providing physicians with an additional treatment option for these blood cancers.

This approval specifically targets patients who have not received prior treatment for CLL/SLL, potentially expanding the patient population that can benefit from this therapeutic approach. The combination therapy represents a significant advancement in the treatment landscape for these hematological malignancies.

Market Implications

The regulatory approval paves the way for AstraZeneca Pharma India Limited to market Acalabrutinib tablets 100 mg for the specified additional indication in the Indian market. However, the company noted that marketing activities remain subject to the receipt of related statutory approvals, if any are required.

This development strengthens the company's position in India's oncology market and provides healthcare professionals with expanded treatment options for patients with CLL and SLL. The approval demonstrates the company's commitment to bringing advanced cancer treatments to Indian patients and expanding access to innovative therapies.

Compliance and Disclosure

AstraZeneca Pharma India Limited disclosed this development under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. The intimation was signed by Tanya Sanish, Company Secretary & Compliance Officer, and communicated to both BSE Limited and National Stock Exchange of India Limited on April 10.

AstraZeneca pharma India has announced plans to sell its substantial 64-acre site located in Bengaluru for Rs 3,400 crore. This significant real estate transaction marks a major strategic move by the pharmaceutical company to divest from its property holdings in the Karnataka capital.

Property Sale Details

The proposed sale involves a considerable land parcel that spans 64 acres in Bengaluru. The transaction value has been set at Rs 3,400 crore, reflecting the premium nature of the property and its strategic location within the city.

Strategic Implications

This divestment represents a significant real estate transaction for AstraZeneca India, indicating the company's strategic approach to optimizing its asset portfolio. The sale of this substantial property asset demonstrates the company's focus on monetizing its real estate holdings in key Indian markets.

The transaction, if completed, would represent one of the larger pharmaceutical sector real estate deals in the Bengaluru market, given the substantial size of the property and the transaction value involved.